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Outpatient Treatment for Pneumothorax Using a Portable 
Small-Bore Chest Tube: A Clinical Report
Won Gi Woo, M.D., Seok Joo, M.D., Geun Dong Lee, M.D., Seok Jin Haam, M.D., Sungsoo Lee, M.D., Ph.D.
Background: For treatment of pneumothorax in Korea, many institutions hospitalize the patient after chest tube 
insertion. In this study, a portable small-bore chest tube (Thoracic Egg; Sumitomo Bakelite Co. Ltd., Tokyo, Japan) 
was used for pneumothorax management in an outpatient clinic. Methods: Between August 2014 and March 2015, 
56 pneumothorax patients were treated using the Thoracic Egg. Results: After Thoracic Egg insertion, 44 patients 
(78.6%) were discharged from the emergency room for follow-up in the outpatient clinic, and 12 patients (21.4%) 
were hospitalized. The mean duration of Thoracic Egg chest tube placement was 4.8 days, and the success rate 
was 73%; 20% of patients showed incomplete expansion and underwent video-assisted thoracoscopic surgery. For pri-
mary spontaneous pneumothorax patients, the success rate of the Thoracic Egg was 76.6% and for iatrogenic pne-
umothorax, it was 100%. There were 2 complications using the Thoracic Egg. Conclusion: Outpatient treatment of 
pneumothorax using the Thoracic Egg could be a good treatment option for primary spontaneous and iatrogenic 
pneumothorax.




Pneumothorax is categorized as primary (without any pre-
cipitating factor), secondary, iatrogenic, and traumatic. 
Usually, primary spontaneous pneumothorax (PSP) is caused 
by subpleural bleb rupture without underlying lung disease 
[1]. Secondary pneumothorax has underlying lung disease, 
such as chronic obstructive pulmonary disease, emphysema, 
asthma, and others, and iatrogenic pneumothorax is usually 
caused by needle puncture of the lung parenchyma during 
acupuncture, central line catheterization, etc. [1].
For treatment of pneumothorax, there is some controversy 
over PSP, but for recurrent pneumothorax, many institutions 
usually recommend video-assisted thoracoscopic surgery (VATS) 
[2]. For PSP, British guidelines recommend needle aspiration 
first, as this may minimize hospitalization and reduce the cost 
to the patient [2]. According to the guidelines of the Ameri-
can College of Chest Physicians, clinically stable patients 
with a large pneumothorax should usually undergo drainage 
by a small-bore catheter (≤14 Fr) or a 16–22 Fr chest tube, 
and hospitalization is recommended [3]. The Japan Society 
for Pneumothorax and Cystic Lung Diseases Guidelines Com-
mittee describe many options, but There is not definite con-
sensus on the treatment for PSP [4]. In this study, we focus on 
outpatient treatment for pneumothorax. We used a portable 
small-bore chest tube (9 Fr) and evaluated its efficacy.
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Fig. 2. Chest X-ray with (A) 12 Fr 
chest tube insertion (arrow) and (B) 
Thoracic Egg (arrows).
Fig. 1. Thoracic Egg catheter.
METHODS
We prospectively collected medical records of pneumo-
thorax patients who underwent portable small-bore chest tube 
(9 Fr, Thoracic Egg; Sumitomo Bakelite Co. Ltd., Tokyo, 
Japan) insertion from August 2014 to March 2015 (Fig. 1). 
Fifty-six patients were followed in the outpatient clinic or 
admitted. After pneumothorax was resolved, we did not rec-
ommend regular outpatient division (OPD) visits. The in-
dication for a portable small-bore chest tube (9 Fr) was a he-
modynamically stable patient without a large pleural effusion 
or hemothorax on chest X-ray, showing costophrenic angle 
blunting, regardless of the cause of pneumothorax (Fig. 2).
To audibly confirm air leakage, we squeezed a plastic 
chamber, and by dipping the chamber in sterile water, we 
could hear and also see air bubbles emerging. However, these 
methods are inconvenient, so if a lung did not expand at fol-
low-up X-ray after 3 to 7 days, we interpreted this to repre-
sent persistent air leakage. Therefore, discharged patients usu-
ally visited the outpatient clinic after one week to evaluate 
improvement in the pneumothorax. If the lung did not show 
full expansion, we recommend surgery as a response to per-
sistent air leakage.
In all patients with an indication for the insertion of a 
portable thoracic drainage device, we used a Thoracic Egg. A 
Thoracic Egg consists of a flexible 9 Fr silicone catheter with 
two one-way Heimlich valves and a small plastic chamber. 
Under local anesthesia, a 5-mm skin incision was made. 
After a test puncture, a catheter was inserted in the third to 
fifth intercostal space in the anterior axillary line. After pleu-
ral puncture, the needle in the catheter was removed, and the 
catheter was inserted into the thoracic cavity. The catheter 
was fixed to the chest wall and connected to a plastic cham-
ber with adhesive tape.
After insertion of the Thoracic Egg, we examined a chest 
X-ray after 30 minutes to 1 hour. We discharged patients 
when (1) the catheter position in the thoracic cavity was con-
firmed, (2) symptoms had resolved, and (3) expansion of the 
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Table 1. Demographic data of the patients
Demographic data Value
Sex (male:female) 47:9
Age (yr) 31 (15–80)
Pneumothorax classification
First spontaneous pneumothorax 37 (66.1)
Recurrent pneumothorax 10 (17.9)
Traumatic pneumothorax 1 (1.8)
Secondary pneumothorax 2 (3.6)
Iatrogenic pneumothorax 6 (10.6)
Site of pneumothorax
Left:right 24:32
Outpatient:inpatient 44 (78.6):12 (21.4)
Duration of Thoracic Egg insertion (day) 4.8 (1–9)
Values are presented as number, mean (range), or number (%), 
unless otherwise stated.
Table 2. Treatment for primary spontaneous pneumothorax (n=37)
Primary spontaneous pneumothorax Number
No recurrence after Thoracic Egg removal 23
Recurrence after Thoracic Egg removal 5
Video-assisted thoracoscopic surgery due to 
incomplete expansion
9
Table 3. Treatment for recurrent pneumothorax (n=10)
Recurrent pneumothorax Number
No recurrence after Thoracic Egg removal 4
Recurrence after Thoracic Egg removal 2
Video-assisted thoracoscopic surgery due to 
incomplete expansion
2
Immediate operation for recurrent case 2
Fig. 3. Treatment results with Thoracic Egg.
lung was confirmed. Usually, we recommended that patients 
visit the outpatient clinic within one week, but we permitted 
admission if a patient preferred inpatient care.
RESULTS
A total of 56 patients were included in this study. Patient 
characteristics are documented in Table 1. The median age 
was 31 years, and 37 (66.0%) were under 30 years old. The 
majority were male (84.0%). By classification of pneumo-
thorax, a first episode of PSP occurred in 37 patients (66.0%), 
recurrent PSP in 10 (17.8%), iatrogenic pneumothorax in 6 
(10.7%), a secondary pneumothorax in 2 (3.6%), and a trau-
matic pneumothorax in one (1.8%). Left side pneumothorax 
occurred in 42.9% (n=24) and right side in 57.1% (n=32).
Forty-four patients (78.6%) were discharged from the emer-
gency room (ER) for follow-up in the outpatient clinic, and 
12 patients (21.4%) were hospitalized because of individual 
needs. The mean duration of Thoracic Egg chest tube place-
ment was 4.8 days. Treatment results with the Thoracic Egg 
are shown in Fig. 3, with a success rate of 73.0%, which was 
indicated by full expansion at the first OPD visit.
Among first episode PSP patients (n=37), 28 showed full 
expansion of the lung, and the chest tube was removed 
(Table 2). Nine patients did not show full expansion and pro-
gressed to VATS surgery. We were able to identify ruptured 
bullae in every patient who underwent surgery [2].
In recurrent pneumothorax patients (n=10), 6 patients showed 
resolution after Thoracic Egg insertion, while 2 patients 
showed incomplete lung expansion and underwent surgery. 
Two patients underwent immediate VATS, because we usu-
ally recommend surgery for recurrences (Table 3).
Iatrogenic pneumothorax patients (n=6) all showed reso-
lution at the OPD visit. The causes of iatrogenic pneumo-
thorax were needle aspiration biopsy, acupuncture, and lung 
injury during central line insertion.
The traumatic pneumothorax patient visited the ER with 
chest pain after falling down from 1 m. Because there was 
not much pleural effusion and the amount of pneumothorax 
was less than ＜50%, we used a Thoracic Egg and admitted 
the patient because of the possibility of delayed hemothorax. 
After 6 days, the patient was discharged without complication 
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following the removal of the Thoracic Egg.
In addition, two secondary pneumothorax patients, who had 
underlying chronic obstructive pulmonary disease, changed to 
a large chest tube 20 Fr or 24 Fr after 3–5 days following 
Thoracic Egg insertion. After 3 days, the patients were dis-
charged without residual pneumothorax.
In summary, of 56 patients who underwent Thoracic Egg 
chest tube insertion, 73.2% (n=41) showed a resolved pneu-
mothorax at the first OPD visit, and 23.2% (n=13) showed a 
residual pneumothorax and underwent surgery (n=11) or re-
placement with a larger tube (n=2) (Fig. 3).
DISCUSSION
Many studies have evaluated the efficacy of small-bore chest 
tubes (7 Fr, 12 Fr, etc.). In a study comparing the efficacy of 
24 Fr and 12 Fr chest tubes, there was no difference in hos-
pital stay (5.6±1.9 days for the 24 Fr group and 5.2±1.5 days 
for the 12 Fr group) or rate of conversion to surgery (35.0% 
for the 24 Fr group and 25.0% for the 12 Fr group) [5]. 
Other studies have reported excellent success rates ranging 
from 84.5% to 97.0% using small-bore catheters (5.5–9.4 Fr) 
for spontaneous pneumothorax [6,7]. In our study, we used a 
9 Fr small bore chest tube, and the overall success rate was 
73.0%.
Some studies have attempted outpatient treatment for pneu-
mothorax. One small, randomized, controlled study compared 
a 12 Fr chest tube with needle aspiration for the treatment of 
PSP [8]. Among 48 patients, 23 underwent needle aspiration. 
Of these, 11 were discharged, and 12 were admitted after 
OPD visits. Of 25 patients who received a 12 Fr chest tube 
insertion with Heimlich valves, 18 were discharged. In this 
study, 60.0% of PSP patient were treated in the OPD.
In our study, the admission rate was 21.4%. Because some 
iatrogenic pneumothorax patients were already inpatients, the 
admission rate was an overestimate. Patients discharged with 
the Thoracic Egg could continue school and social activities. 
It will give patients social and economic benefits with re-
duced costs due to hospitalization. With the small size of the 
catheter, patients also felt more comfortable.
Use of a small bore catheter may lead to kinking or block-
age [9]. There were two complications in this study. One pa-
tient had worsening of the pneumothorax because of catheter 
kinking, and another experienced a tension pneumothorax be-
cause of disconnection of the catheter from the plastic cha-
mber. These two patients ultimately showed full expansion of 
the lung after management of the catheter and chamber. There 
were no other complications.
A similar study in Japan for treatment of PSP using the 
Thoracic Egg showed a success rate of 95.8%; 32.9% of the 
patients had a recurrent pneumothorax and received other 
treatments. In that study, the only indication for Thoracic Egg 
insertion was PSP [9].
In our study design, we used the Thoracic Egg regardless 
of pneumothorax type, except in patients with large effusions 
or a hemothorax. For first-episode PSP patients, the success 
rate was 75.6% (28/37); 37.8% (14/37) had recurrent pneu-
mothorax and 24.0% (9/37) underwent VATS. In iatrogenic 
pneumothorax, the Thoracic Egg success rate was 100.0%. 
For recurrent pneumothorax patients, it was 60.0%. In addi-
tion, among patients with incomplete expansion of the lung 
after Thoracic Egg insertion, all had bullae on VATS ins-
pection.
This study had several limitations. Because most patients 
were young, they were able to continue daily social activities 
with the Thoracic Egg. However, it was difficult to calculate 
the socioeconomic effect or cost savings. Moreover, some 
physicians did not favor use of the Thoracic Egg, resulting in 
some bias.
A portable small-bore chest tube, the Thoracic Egg, shows 
comparable results with other studies managing pneumothorax 
after hospitalization. In our institution, we provided initial 
treatment options to pneumothorax patients. The majority 
were young, and preferred to be discharged with the Thoracic 
Egg, enabling them to continue work and other activities. 
Thus, Thoracic Egg insertion can provide social and econom-
ic benefits for patients.
In conclusion, there are many treatment options for 
pneumothorax. This study showed comparable results with 
OPD treatment using the Thoracic Egg, with fewer com-
plications. And most patients could continue daily activity 
with the Thoracic Egg. In this aspect, the treatment may have 
social and economic benefits. Therefore, the Thoracic Egg 
may be a good treatment option for pneumothorax.
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